arterioscope

arterioscope

PLATFORM FOR NON-INVASIVE DIAGNOSTICS OF BIOMARKERS FOR CARDIOVASCULAR HEALTH

Innovation in non-invasive diagnostics of biomarkers using Artificial Intelligence

arterioscope is a spin-off from the Technical University of Graz and the result of a strategic lead project initiated in 2018. It emerged from intensive collaboration between science and industry. Our patented technology is an innovative approach to revolutionize the way we understand and treat cardiovascular diseases.

Our Solution

arterioscope is an AI-driven software for OEMs, pharmaceutical companies, and hospitals for the diagnosis of biomarkers associated with cardiovascular diseases such as heart failure, myocardial infarction, or atherosclerosis. By evaluating time series data from ECG (Electrocardiography), PPG (Photoplethysmography), or IPG (Impedance Plethysmography), we can measure various biomarkers, such as BNP, non-invasively and in real-time. This approach saves hospitals valuable time and can reduce diagnostic costs by 80%.

Mission

arterioscope aims to become a pioneer in non-invasive diagnostics for cardiovascular diseases. With our advanced technology, we can significantly lower diagnostic costs and improve the quality of patient care. For example, through our preventive approach, we can detect cardiovascular complications arising from diabetes early.

Team:

Hermann Moser, Co-Founder & CEO / Vahid Badeli, Co-Founder & CTO /
Sascha Ranftl, Co-Founder & CSO

Social Media Channels

LinkedIn

Instagram

Contact: Hermann Moser (hermann.moser@arterioscope.com)
Website: https://www.arterioscope.com